Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
Seon Ha Baek, Hyunsuk Kim, Jeonghwan Lee, Dong Ki Kim, Kook-Hwan Oh, Yon Su Kim, Jin Suk Han, Tae Min Kim, Se-Hoon Lee, Kwon-Wook Joo
Korean J Intern Med. 2014;29(1):40-48.   Published online 2014 Jan 2     DOI: https://doi.org/10.3904/kjim.2014.29.1.40
Citations to this article as recorded by Crossref logo
Surveillance de l’hypertension artérielle chez les patients traités par anti-angiogénique par voie orale en pratique quotidienne
Lisa Belaid, Sahar Bayat-Makoei, Brigitte Laguerre, Cécile Vigneau
Néphrologie & Thérapeutique.2018; 14(2): 99.     CrossRef
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
Yassir Sbitti, Adil Debbagh, Khaoula Slimani, Mohamed Mahi, Hassan Errihani, Mohamed Ichou
Journal of Medical Case Reports.2018;[Epub]     CrossRef
Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
Yoshitaka Furuto, Hirotsugu Hashimoto, Akio Namikawa, Haruki Outi, Hiroko Takahashi, Hajime Horiuti, Kazuho Honda, Yuko Shibuya
BMC Nephrology.2018;[Epub]     CrossRef
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
Hiroki Ishihara, Tsunenori Kondo, Hironori Fukuda, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe
Japanese Journal of Clinical Oncology.2017; 47(12): 1175.     CrossRef
Dasatinib-induced nephrotic syndrome
Taichi Hirano, Miyuki Hashimoto, Yu Korogi, Takahiro Tsuji, Kei Miyanaka, Hiroshi Yamasaki, Hiroyuki Tsuda
Leukemia & Lymphoma.2016; 57(3): 726.     CrossRef
Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi
Clinical Genitourinary Cancer.2016; 14(4): 314.     CrossRef
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma
Dong-Hoe Koo, Inkeun Park, Jin-Hee Ahn, Dae-Ho Lee, Dalsan You, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Jae-Lyun Lee
Cancer Chemotherapy and Pharmacology.2016; 77(2): 339.     CrossRef
Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma
Hironori Fukuda, Tsunenori Kondo, Shoichi Iida, Toshio Takagi, Kazunari Tanabe
Urologic Oncology: Seminars and Original Investigations.2016; 34(8): 338.e1.     CrossRef
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
Aleksandra Semeniuk-Wojtaś, Arkadiusz Lubas, Rafał Stec, Cezary Szczylik, Stanisław Niemczyk
International Journal of Molecular Sciences.2016; 17(12): 2073.     CrossRef
Inhibition of the VEGF signalling pathway and glomerular disorders
Mario Ollero, Djillali Sahali
Nephrology Dialysis Transplantation.2015; 30(9): 1449.     CrossRef
Sunitinib
Reactions Weekly.2015; 1548(1): 248.     CrossRef
Risks associated with sunitinib use and monitoring to improve patient outcomes
Bum Soon Choi
The Korean Journal of Internal Medicine.2014; 29(1): 23.     CrossRef